Day 2Drug-eluting stentsPharmacology

SOLACI 2017 | BRS: Present & Future

solaci
solaci
542
0
Dr. Stephen Ellis
Dr. Stephen Ellis

Read articles on the main presentations of the second day of SOLACI-CACI 2017 Congress.

See the presentation by Dr. Stephen Ellis, entitled “BRS: Presente y Futuro”.

3Ellis-Steve(3)presentandfuture

Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

Previous article
SOLACI CACI 2017 | BRS: Presente y Futuro
Next article
SOLACI CACI 2017 | Practical application of Quality Improvement projects: How to make it work
solaci
solaci

More articles by this author

Low-Dose Rivaroxaban After Peripheral Angioplasty: Effectiveness and Safety in Real-World Clinical Practice

Dr. Juan Manuel Pérez - 0
Following lower limb revascularization, optimal medical therapy includes antiplatelet agents, high-intensity statins, and control of cardiovascular risk factors. Recent studies such as COMPASS and...

How real are the adverse effects of statins? Evidence from randomized clinical trials

Dr. Juan Manuel Pérez - 0
The safety of statins continues to be a subject of debate, partly due to the extensive list of adverse effects included in prescribing information,...

Morpheus Global Registry: Safety and efficacy of the long tapered BioMime™ Morph stent in complex coronary lesions

Dr. Juan Manuel Pérez - 0
Percutaneous coronary intervention in long coronary lesions continues to represent a technical and clinical challenge, in which the use of conventional cylindrical stents may...

Is it safe to use negative chronotropic drugs early after TAVI?

Dr. Juan Manuel Pérez - 0
TAVI is associated with a relevant incidence of conduction system disturbances and the development of atrioventricular block that may require permanent pacemaker implantation. Many...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Antithrombotic Anticoagulants

Low-Dose Rivaroxaban After Peripheral Angioplasty: Effectiveness and Safety in Real-World Clinical Practice

Following lower limb revascularization, optimal medical therapy includes antiplatelet agents, high-intensity statins, and control of cardiovascular risk factors. Recent studies...
Dr. Juan Manuel Pérez -
SOLACI Sessionsspot_img

Recent Articles

Low-Dose Rivaroxaban After Peripheral Angioplasty: Effectiveness and Safety in Real-World Clinical Practice

Dr. Juan Manuel Pérez - 0
Following lower limb revascularization, optimal medical therapy includes antiplatelet agents, high-intensity statins, and control of cardiovascular risk factors. Recent studies such as COMPASS and...

Sheathless Femoral Impella: A New Strategy to Reduce Vascular Complications in High-Risk PCI?

Dr. Juan Manuel Pérez - 0
Patients with complex coronary artery disease or cardiogenic shock undergoing percutaneous coronary intervention (PCI) may benefit from the hemodynamic support provided by percutaneous ventricular...

OCT- and IVUS-Guided Coronary Angioplasty in Acute Coronary Syndrome: Long-Term Clinical Outcomes

Dr. Andrés Rodríguez - 0
Percutaneous coronary angioplasty (PCI) in patients with acute coronary syndrome (ACS) has reduced mortality in the acute phase. However, recurrent ACS and target vessel...